Maximising data capture in obesity trials

ICON’s pragmatic DXA strategy captures complete visceral fat datasets, preventing “silent attrition” and protecting trial integrity, timelines, and budgets. Scale GLP-1 obesity trials without losing DXA data. Credit via Shutterstock. Global obesity trials are scaling fast with GLP‑1 therapies, making complete data capture essential to preserve scientific integrity and timelines. ICON implemented a pragmatic DXA strategy—modified hand positioning and a dual‑scan workflow with centralized review—that preserved full visceral fat datasets, preventing “silent attrition” from incomplete imaging. You will receive an email shortly. Please check your inbox to download the Report. By downloading this Report, you acknowledge that GlobalData may share…

Source: Clinical Trials Arena